- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00030420
Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer
Evaluation Of Celecoxib In Combination With Docetaxel In The Treatment Of Advanced Non-Small Cell Lung Cancer Patients Previously Treated With Platinum Based Chemotherapy
RATIONALE: Celecoxib may slow the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with celecoxib may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining celecoxib and docetaxel in treating patients who have advanced non-small cell lung cancer that has been previously treated with platinum-based chemotherapy.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
- Determine the efficacy and feasibility of celecoxib combined with docetaxel in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
- Determine the response rate of patients treated with this regimen.
- Determine the toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral celecoxib twice daily (beginning on day -7 of the first course) and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses after CR. Patients who achieve stable disease (SD) or a partial response (PR) receive a minimum of 2 additional courses after SD or PR. At the discretion of the treating physician, patients then receive maintenance therapy comprising celecoxib only.
Patients who discontinue therapy for disease progression or unacceptable toxicity are followed for at least 6 months.
PROJECTED ACCRUAL: A total of 21-39 patients will be accrued for this study within 13-28 months.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Michigan
-
Detroit, Michigan, Vereinigte Staaten, 48201-1379
- Barbara Ann Karmanos Cancer Institute
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Diagnosis of stage IIIA, IIIB, or IV non-small cell lung cancer
- Disease progression during or after 1 or more platinum-based chemotherapy regimens
- Measurable or evaluable disease
No symptomatic or untreated brain or leptomeningeal metastases
- Previously treated patients must be neurologically stable for 4 weeks after completion of appropriate therapy
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- SWOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 8 g/dL
Hepatic:
- Bilirubin no greater than upper limit of normal (ULN)
- AST/ALT no greater than ULN (or no greater than 2.5 times ULN if alkaline phosphatase no greater than ULN)
- Alkaline phosphatase no greater than ULN (or no greater than 5 times ULN if AST/ALT no greater than ULN)
- No history of chronic hepatitis of any duration
Renal:
- Creatinine no greater than ULN
Cardiovascular:
- No uncontrolled congestive heart failure
- No uncontrolled angina
- No myocardial infarction and/or stroke within the past 6 months
- No active thromboembolic event within the past 4 weeks
Gastrointestinal:
- No gastrointestinal bleeding within the past 6 months
- No history of peptic ulcer disease
Other:
- No prior hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
- No prior allergy to any non-steroidal anti-inflammatory drug
- No other prior or concurrent malignancy within the past 3 years except adequately treated squamous cell or basal cell skin cancer or carcinoma in situ of the cervix
- No grade 2 or greater peripheral neuropathy
- No active infection
- No other serious concurrent medical illness
- No history of dementia, active psychiatric disorder, or other condition that would interfere with ability to take oral medication or preclude compliance with study
- HIV negative
- Must weigh at least 50 kg (110 pounds)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- See Disease Characteristics
- At least 4 weeks since prior chemotherapy
- Prior paclitaxel allowed
- No prior docetaxel
Endocrine therapy:
- At least 3 days since prior steroids
Radiotherapy:
- At least 4 weeks since prior radiotherapy
- No prior radiotherapy to target lesion
Surgery:
- At least 4 weeks since prior major surgery
Other:
- Prior intermittent use of non-steroidal anti-inflammatory drugs (NSAIDs), including rofecoxib or celecoxib, allowed
- At least 1 week since prior fluconazole
- No recent prior NSAIDs, including rofecoxib or celecoxib, for a duration of more than 30 consecutive days
- No concurrent fluconazole or lithium
- No other concurrent NSAIDs except aspirin administered at a dose of no more than 325 mg/day for cardiovascular conditions
- No other concurrent cyclo-oxygenase-2 inhibitors
- No other concurrent investigational agents
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Celecoxib & Docetaxel
Celecoxib: 400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment. Doctaxel: Day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days |
400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.
Andere Namen:
On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Efficacy of combining Celecoxib with Docetaxel
Zeitfenster: Weeks 1 , 2 and 3
|
Blood levels of VEGF & PGE2
|
Weeks 1 , 2 and 3
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Response rate of Celecoxib and Docetaxel
Zeitfenster: Every 2 cycles (or every 42 days); After therapy is completed or if the patient is only on Celecoxib, will be assessed for progression every month by clinical exam and every 3 months by radiological evaluation.
|
CT Chest/Abdomen
|
Every 2 cycles (or every 42 days); After therapy is completed or if the patient is only on Celecoxib, will be assessed for progression every month by clinical exam and every 3 months by radiological evaluation.
|
Toxicity of Celecoxib and Docetaxel
Zeitfenster: Every week
|
Routine bloodwork
|
Every week
|
Expression of cyclooxygenase-2 (COX-2) in tumors
Zeitfenster: Pre-study
|
Tissue sample from initial diagnosis, parrafin embedded tissue block
|
Pre-study
|
Changes in plasma levels of prostaglandin E2 (PGE2) & vascular endthelial growth factor (VEGF)
Zeitfenster: Pre-study; Weeks 1 , 2 and 3
|
Collecting blood plasma
|
Pre-study; Weeks 1 , 2 and 3
|
Vascular changes induced in the tumor by celecoxib
Zeitfenster: Weeks 1, 3 & 6
|
Using DCE-MRI and PET scans to evaluate.
|
Weeks 1, 3 & 6
|
Mitarbeiter und Ermittler
Mitarbeiter
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen der Atemwege
- Neubildungen
- Lungenkrankheit
- Neubildungen nach Standort
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Karzinom, bronchogen
- Bronchiale Neubildungen
- Lungentumoren
- Karzinom, nicht-kleinzellige Lunge
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Agenten des peripheren Nervensystems
- Enzym-Inhibitoren
- Analgetika
- Agenten des sensorischen Systems
- Entzündungshemmende Mittel, nichtsteroidal
- Analgetika, nicht narkotisch
- Entzündungshemmende Mittel
- Antirheumatika
- Cyclooxygenase-Inhibitoren
- Antineoplastische Mittel
- Tubulin-Modulatoren
- Antimitotische Mittel
- Mitose-Modulatoren
- Cyclooxygenase-2-Inhibitoren
- Docetaxel
- Celecoxib
Andere Studien-ID-Nummern
- CDR0000069164
- P30CA022453 (US NIH Stipendium/Vertrag)
- WSU-C-2304 (Andere Kennung: Barbara Ann Karmanos Cancer Institute)
- NCI-V01-1688
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Lungenkrebs
-
Hal C CharlesAbgeschlossenKonstriktive Bronchiolitis | Irak-Afganistan War Lung Injury SyndromeVereinigte Staaten
-
Joseph MccuneEunice Kennedy Shriver National Institute of Child Health and Human Development... und andere MitarbeiterBeendetLupus erythematodes, systemisch | Systemische Vaskulitis | Lungenerkrankung mit systemischer Sklerose | Isolierte Angiitis des zentralen Nervensystems | Lung Disease Interstitial DiffusVereinigte Staaten
Klinische Studien zur Celecoxib
-
Chong Kun Dang PharmaceuticalAbgeschlossenArthrose-HandKorea, Republik von
-
Hoffmann-La RocheAbgeschlossenRheumatoide ArthritisRussische Föderation
-
Seoul National University HospitalAbgeschlossenHirnblutungKorea, Republik von
-
Targeted Therapy Technologies, LLCRekrutierungMakulaödem | Epiretinale Membran | Venenastverschluss | Strahlen-Retinopathie | Zentrale seröse Retinopathie mit Papillengrube | Commotio retinae | VitritisVereinigte Staaten
-
Yooyoung Pharmaceutical Co., Ltd.CliPS Co., LtdAbgeschlossenArthrose, KnieKorea, Republik von
-
Yooyoung Pharmaceutical Co., Ltd.CliPSBnCRekrutierungArthrose, KnieKorea, Republik von
-
Amsterdam UMC, location VUmcNetherlands Brain FoundationRekrutierungEntzündung | Depressive Störung, MajorNiederlande
-
Dr. Reddy's Laboratories LimitedAbgeschlossenAkuter SchmerzVereinigte Staaten
-
Xintian PharmaceuticalNoch keine Rekrutierung
-
Samsung Medical CenterThe Korean Urological AssociationZurückgezogenBenigne ProstatahyperplasieKorea, Republik von